Search for other papers by Rebeca Esquivel-Zuniga in
Google Scholar
PubMed
Search for other papers by Alan D Rogol in
Google Scholar
PubMed
hypogonadotropic hypogonadism, primary hypogonadism and functional hypogonadism, which must be considered in adolescents with DP. Hypogonadism and its medical and psychological consequences can be underestimated or overlooked in patients with chronic illness
Search for other papers by Nandini Shankara Narayana in
Google Scholar
PubMed
Search for other papers by Lam P Ly in
Google Scholar
PubMed
Search for other papers by Veena Jayadev in
Google Scholar
PubMed
Search for other papers by Carolyn Fennell in
Google Scholar
PubMed
Search for other papers by Sasha Savkovic in
Google Scholar
PubMed
Search for other papers by Ann J Conway in
Google Scholar
PubMed
Search for other papers by David J Handelsman in
Google Scholar
PubMed
data of patients. Men were divided into primary (hypergonadotrophic), secondary (hypogonadotrophic) hypogonadism or transmen groups with the causes of hypogonadism described previously ( 14 ). Injections were administered by experienced nurses
Search for other papers by Shruti Khare in
Google Scholar
PubMed
Search for other papers by Anurag R Lila in
Google Scholar
PubMed
Search for other papers by Hiren Patt in
Google Scholar
PubMed
Search for other papers by Chaitanya Yerawar in
Google Scholar
PubMed
Search for other papers by Manjunath Goroshi in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
=45/50) had resumption of regular menses. In the male patients where baseline biochemistry was available, 62.5% ( n =20/32) had recovery of hypogonadism i.e., normalisation of testosterone. Twelve patients who were referred post-primary TSS had
Search for other papers by Rui-yi Tang in
Google Scholar
PubMed
Search for other papers by Rong Chen in
Google Scholar
PubMed
Search for other papers by Miao Ma in
Google Scholar
PubMed
Search for other papers by Shou-qing Lin in
Google Scholar
PubMed
Search for other papers by Yi-wen Zhang in
Google Scholar
PubMed
Search for other papers by Ya-ping Wang in
Google Scholar
PubMed
Introduction Idiopathic hypogonadotropic hypogonadism (IHH) is also known as congenital hypogonadotropic hypogonadism. This rare clinically and genetically heterogeneous disorder is characterized by complete or partial pubertal failure, which
Department of Endocrinology and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Martine Cools in
Google Scholar
PubMed
Search for other papers by Stamatina Ioakim in
Google Scholar
PubMed
Search for other papers by S Faisal Ahmed in
Google Scholar
PubMed
Search for other papers by Silvia Andonova in
Google Scholar
PubMed
Search for other papers by Magdalena Avbelj-Stefanija in
Google Scholar
PubMed
Search for other papers by Federico Baronio in
Google Scholar
PubMed
Search for other papers by Jerome Bouligand in
Google Scholar
PubMed
Search for other papers by Hennie T Bruggenwirth in
Google Scholar
PubMed
Search for other papers by Justin H Davies in
Google Scholar
PubMed
Search for other papers by Elfride De Baere in
Google Scholar
PubMed
Search for other papers by Iveta Dzivite-Krisane in
Google Scholar
PubMed
Search for other papers by Paula Fernandez-Alvarez in
Google Scholar
PubMed
Search for other papers by Alexander Gheldof in
Google Scholar
PubMed
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
Search for other papers by Claudia Giavoli in
Google Scholar
PubMed
Search for other papers by Claus H Gravholt in
Google Scholar
PubMed
Search for other papers by Olaf Hiort in
Google Scholar
PubMed
Search for other papers by Paul-Martin Holterhus in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by Csilla Krausz in
Google Scholar
PubMed
Search for other papers by Kristina Lagerstedt-Robinson in
Google Scholar
PubMed
West of Scotland Centre for Genomic Medicine, Queen Elizabeth University Hospital, Glasgow, United Kingdom
Search for other papers by Ruth McGowan in
Google Scholar
PubMed
Search for other papers by Uta Neumann in
Google Scholar
PubMed
Search for other papers by Antonio Novelli in
Google Scholar
PubMed
Search for other papers by Xavier Peyrassol in
Google Scholar
PubMed
Search for other papers by Leonidas A Phylactou in
Google Scholar
PubMed
Search for other papers by Julia Rohayem in
Google Scholar
PubMed
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
Search for other papers by Dineke Westra in
Google Scholar
PubMed
Search for other papers by Valeria Vezzoli in
Google Scholar
PubMed
Search for other papers by Raffaella Rossetti in
Google Scholar
PubMed
hypogonadism (CHH) or unexplained 46,XX primary ovarian insufficiency (POI). These conditions are rare, with variable and complex aetiology, and their differential diagnosis using only clinical and biochemical parameters may be difficult ( 3 ). Therefore, NGS
Search for other papers by Milou Cecilia Madsen in
Google Scholar
PubMed
Search for other papers by Martin den Heijer in
Google Scholar
PubMed
Search for other papers by Claudia Pees in
Google Scholar
PubMed
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
Search for other papers by Leontine E H Bakker in
Google Scholar
PubMed
concentrations in males can lead to a clinical syndrome known as male hypogonadism. This can be caused by testicular disease (primary hypogonadism) or central, pituitary, or hypothalamic disease (secondary hypogonadism). Causes can be genetic, like in Klinefelter
Search for other papers by L M Mongioì in
Google Scholar
PubMed
Search for other papers by R A Condorelli in
Google Scholar
PubMed
Search for other papers by S La Vignera in
Google Scholar
PubMed
Search for other papers by A E Calogero in
Google Scholar
PubMed
Introduction Adrenal insufficiency (AI) is a disease caused by either primary adrenal failure (Addison’s disease, over 90% due to autoimmune adrenalitis) ( 1 ) or by hypothalamic–pituitary impairment of the corticotropic axis alone or in
Search for other papers by Giuseppe Grande in
Google Scholar
PubMed
Search for other papers by Andrea Graziani in
Google Scholar
PubMed
Search for other papers by Antonella Di Mambro in
Google Scholar
PubMed
Search for other papers by Riccardo Selice in
Google Scholar
PubMed
Department of Medicine, University of Padova, Padova, Italy
Search for other papers by Alberto Ferlin in
Google Scholar
PubMed
consensus nowadays is that 25-OH-D3 levels might represent a marker of Leydig cell function, being reduced not only in men with low testosterone (both primary and secondary hypogonadism) but also in men with subclinical hypogonadism. Vitamin D is essential
Search for other papers by Amar Osmancevic in
Google Scholar
PubMed
Search for other papers by Kristin Ottarsdottir in
Google Scholar
PubMed
Search for other papers by Margareta Hellgren in
Google Scholar
PubMed
Search for other papers by Ulf Lindblad in
Google Scholar
PubMed
Search for other papers by Bledar Daka in
Google Scholar
PubMed
. ( https://doi.org/10.2164/jandrol.111.015065 ) 27 Tajar A Forti G O’Neill TW Lee DM Silman AJ Finn JD Bartfai G Boonen S Casanueva FF Giwercman A , Characteristics of secondary, primary, and compensated hypogonadism in aging men
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Niels Jørgensen in
Google Scholar
PubMed
gonadotropins have been documented in other clinical conditions such as anorexia nervosa ( 34 ), polycystic ovarian disease ( 35 ) and primary male hypogonadism ( 36 ). Thus, as for TSH, immunoreactive FSH and LH may not reflect FSH and LH bioactivity in